Pharmacokinetic parameters of genotoxic activity inferred from the comparison of the kinetics of MN-PCE induced by chemical agents and ionizing radiation.
Some kinetic parameters of clastogenic activity of cyclophosphamide were inferred by means of the comparison of its kinetics of micronucleated polychromatic erythrocytes (MN-PCE) formation with the kinetics induced by radiation. The same reasoning was also applied to the kinetics obtained by treatment with mitomycin C (MMC), arabinocyl cytosine (Ara-C) and 6-mercaptopurine (6-MOP), based on previously reported data from the literature. The results indicate that the latency period (LP) and half-lives (HL) vary from one mutagen to another. For MMC, they are very similar to radiation indicating a rapid distribution and reaction. CP presents very long LP and HL which agree with the requirement of mutagen activation. Ara-C showed a very short LP which suggests a rapid activation and fast induction of damage in DNA. 6-MOP presented a very long LP which agreed with the requirement of its incorporation into DNA to cause micronucleus (MN). From the data obtained in the present work, it can be concluded that the comparison of the kinetics of MN-PCE formation induced by chemical agents with that obtained by the exposure to an acute dose of radiation permits one to estimate some parameters of the kinetics of clastogenic activity of chemical agents, like the LP and the HL. This seems to be valid for agents that act through the induction of DNA lesions; in the case of agents whose clastogenic activity is through other mechanisms, such as the inhibition or alteration of the process of duplication of the DNA, the kinetic parameters are not equivalent to the LP and HL; however, they could provide information on their possible mechanism of action.
Morales-Ramírez
P
P
Departamento de Genética, Instituto Nacional de Investigaciones Nucleares, Mexico D.F.
Vallarino-Kelly
T
T
Anguiano-Orozco
G
G
Rodríguez-Reyes
R
R
D000818:Animals; D003520:Cyclophosphamide / Q000493:pharmacokinetics / Q000633:toxicity; D003561:Cytarabine / Q000493:pharmacokinetics / Q000633:toxicity; D004307:Dose-Response Relationship, Radiation; D004912:Erythrocytes / Q000187:drug effects* / Q000502:physiology / Q000528:radiation effects*; D008297:Male; D015122:Mercaptopurine / Q000633:toxicity; D051379:Mice; D008807:Mice, Inbred BALB C; D048629:Micronuclei, Chromosome-Defective / Q000187:drug effects* / Q000235:genetics / Q000528:radiation effects*; D015162:Micronucleus Tests / Q000379:methods*; D016685:Mitomycin / Q000493:pharmacokinetics / Q000633:toxicity; D009153:Mutagens / Q000633:toxicity; D019384:Nucleic Acid Synthesis Inhibitors / Q000493:pharmacokinetics / Q000633:toxicity
D009153:Mutagens; D019384:Nucleic Acid Synthesis Inhibitors; D003561:Cytarabine; D016685:Mitomycin; D003520:Cyclophosphamide; D015122:Mercaptopurine